Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Completed 21Terminated 7Unknown 5Withdrawn 4Recruiting 3Active not recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1

Conditions

Multiple Myeloma 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Neoplasms, Plasma Cell 14Recurrence 12Leukemia 12Vomiting 11Lymphoma, Extranodal NK-T-Cell 11Lymphoma 11Neoplasms 9Nausea 6Lymphoma, Mantle-Cell 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Paraproteinemias 3Lymphoma, T-Cell, Peripheral 3Lymphoma, B-Cell, Marginal Zone 3Lymphohistiocytosis, Hemophagocytic 3Lung Neoplasms 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Diseases 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Burkitt Lymphoma 3Breast Neoplasms 3Blood Protein Disorders 3Renal Insufficiency 2Postoperative Nausea and Vomiting 2Polycystic Ovary Syndrome 2Peripheral Nervous System Diseases 2

Interventions

Rituximab 55Cyclophosphamide 38Vincristine 25Prednisone 24Doxorubicin 21Cytarabine 18Etoposide 17Lenalidomide 16Gemcitabine 12Melphalan 8Filgrastim 8Cisplatin 8Peripheral Blood Stem Cell Transplantation 7Oxaliplatin 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7Methotrexate 7Ifosfamide 7Carmustine 7zanubrutinib 6R-CHOP protocol 6Vindesine 5Radiotherapy 5Dexamethasone 5Busulfan 5ibrutinib 4fludarabine phosphate 4Methylprednisolone 4Epirubicin 4Decitabine 4Cyclosporine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Large B-Cell, Diffuse × Dexamethasone × Clear all
NCT03837873 2022-01-26

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Unknown
118 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02733380 2020-04-01

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Henan Cancer Hospital

Phase 2 Unknown
20 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02542111 2017-11-14

A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL

Ruijin Hospital

Phase 2 Unknown
30 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT00002481 2013-12-18

Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Unknown
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01066429 2010-02-12

DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma

Hospital Universitario Principe de Asturias

Phase 2 Unknown
30 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡